SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process can be delayed.

Drug Requested: Enbrel® (etanercept)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
Member Sentara #:	
Prescriber Name:	
	Date:
Office Contact Name:	
	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Autho	
Drug Form/Strength:	
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:

<u>NOTE</u>: Sentara Health considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has <u>NOT</u> been established and will <u>NOT</u> be permitted.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Diagnosis: Rheumatoid Arthritis Dosing: SubQ: 50 mg once weekly

- □ Member has a diagnosis of moderate-to-severe active **rheumatoid arthritis**
- **D** Prescribed by or in consultation with a **Rheumatologist**

- □ Member has tried and failed at least <u>ONE</u> of the following **DMARD** therapies for at least <u>three (3)</u> <u>months</u>
 - □ hydroxychloroquine
 - □ leflunomide
 - □ methotrexate
 - □ sulfasalazine

Diagnosis: Polyarticular Juvenile Idiopathic Arthritis Dosing:

- Weight < 63 kg: SubQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose
- Weight \geq 63 kg: SubQ: 50 mg once weekly
- □ Member has a diagnosis of moderate-to-severe active polyarticular juvenile idiopathic arthritis
- **D** Prescribed by or in consultation with a **Rheumatologist**
- $\Box \quad \text{Member is} \ge 2 \text{ years of age}$
- □ Member has tried and failed at least <u>ONE</u> of the following DMARD therapies for at least <u>three (3)</u> <u>months</u>
 - □ cyclosporine
 - □ hydroxychloroquine
 - □ leflunomide
 - □ methotrexate
 - □ non-steroidal anti-inflammatory drugs (NSAIDs)
 - oral corticosteroids
 - □ sulfasalazine
 - □ tacrolimus

Diagnosis: Psoriatic Arthritis Dosing: SubQ: 50 mg once weekly

- □ Member has a diagnosis of active **psoriatic arthritis**
- **D** Prescribed by or in consultation with a **Rheumatologist**
- $\Box \quad \text{Member is} \ge 2 \text{ years of age}$
- □ Member has tried and failed at least <u>ONE</u> of the following DMARD therapies for at least <u>three (3)</u> <u>months</u>
 - □ cyclosporine
 - □ leflunomide
 - □ methotrexate
 - □ sulfasalazine

Diagnosis: Ankylosing Spondylitis Dosing: SubQ: 50 mg once weekly

- □ Member has a diagnosis of active **ankylosing spondylitis**
- **D** Prescribed by or in consultation with a **Rheumatologist**
- □ Member tried and failed, has a contraindication, or intolerance to <u>**TWO**</u> NSAIDs

Diagnosis: Plaque Psoriasis

Dosing: SubQ: Initial: 50 mg twice weekly for 3 months. Maintenance: 50 mg once weekly

- □ Member has a diagnosis of moderate-to-severe chronic **plaque psoriasis**
- **D** Prescribed by or in consultation with a **Dermatologist**
- $\Box \quad \text{Member is} \ge 4 \text{ years of age}$
- □ Member tried and failed at least <u>ONE</u> of either Phototherapy or Alternative Systemic Therapy for at least <u>three (3) months</u> (check each tried below):

<u>Phototherapy</u>: UV Light Therapy NB UV-B

D PUVA

□ <u>Alternative Systemic Therapy</u>:

- Oral Medications
 - □ acitretin
 - □ methotrexate
 - □ cyclosporine

Medication being provided by Specialty Pharmacy – Proprium Rx

** Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>

*Approved by Pharmacy & Therapeutics Committee: 9/17/2009; 11/16/2023

REVISED/UPDATED: 6/3/2011; 8/12/2011; 1/16/2014; 2/5/2014; 2/25/2014; 4/3/2014; 4/28/2014; 5/2/2014; 8/8/2014; 10/30/2014; 5/21/2015; 12/27/2015; 8/12/2016; 9/22/2016; 12/11/2016; 8/3/2017; 12/11/2017; 1/2/2018; 1/11/2018; 11/24/2018; 9/28/2019; 11/26/2019; 2/4/2022; 12/2022; 12/11/2023